Studienportal Eierstockkrebs

Ovarian cancer study portal logo
Menu
  • Welcome to
  • Study overview
  • Map of Germany
  • Frequently asked questions
  • About ovarian cancer
  • English
    • German
    • Ukrainian
    • Turkish
    • Arabic
    • Vietnamese
    • Polish

Imprint

Imprint

Idea and management:
Prof. Dr. med. hc. Dr. Jalid Sehouli
Susanne Fechner

Editing and coordination:
AVISOmed medizin+media

Web design:
Christian Suhr

Contact:
AVISOmed medizin+media
Friedelstr. 56
12047 Berlin
+49 30 346 496 459
info@avisomed.de
www.avisomed.de

Responsible for the content (according to § 55 Abs. 2 RStV):
Susanne Fechner

An initiative of Forum Gyn Onkologie in cooperation with the German Ovarian Cancer Foundation, NOGGO e.V. and the AGO Study Group.

News from science and practice

Highlights from ESGO 2026 and new approval!

New final data: Immunotherapy with atezolizumab brings no additional benefit in recurrent ovarian cancer

Study objective achieved! – Results of the ROSELLA study

News for patients with platinum-resistant ovarian cancer

New study data from ESMO 2025 – Immunotherapy brings survival benefit in platinum-resistant ovarian cancer for the first time

© Ovarian cancer study portal Imprint | Privacy | Contact | Helpful links

E-mail: info@avisomed.de

  • English
  • Deutsch
  • Українська
  • Türkçe
  • العربية
  • Tiếng Việt
  • Polski